Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Pitfalls in anatomic pathology and clinical oncology: a case of misdiagnosed pulmonary Ewing sarcoma as SCLC.

Frontiers in oncology·2025
Same author

Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.

Discover oncology·2025
Same author

Autosomal genetics and Y-chromosome haplogroup L1b-M317 reveal Mount Lebanon Maronites as a persistently non-emigrating population.

European journal of human genetics : EJHG·2020
Same author

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen.

Brain sciences·2020
Same author

Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments.

BMC medical genomics·2019
Same author

Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.

Clinical neurology and neurosurgery·2019
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Brain metastases.

Francois G Kamar1, Jerome B Posner

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Seminars in Neurology
|June 26, 2010
PubMed
Summary
This summary is machine-generated.

Brain metastases affect about 10% of cancer patients and are increasingly common. Effective treatment improves quality of life, but careful management of symptoms and side effects is crucial.

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Modelling Brain Metastasis: Standardized Analysis of Metastatic Colonization and Histological Growth Patterns by Stereotactic Intracortical Injection
07:42

Modelling Brain Metastasis: Standardized Analysis of Metastatic Colonization and Histological Growth Patterns by Stereotactic Intracortical Injection

Published on: January 16, 2026

Related Experiment Videos

Last Updated: Jun 12, 2026

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Modelling Brain Metastasis: Standardized Analysis of Metastatic Colonization and Histological Growth Patterns by Stereotactic Intracortical Injection
07:42

Modelling Brain Metastasis: Standardized Analysis of Metastatic Colonization and Histological Growth Patterns by Stereotactic Intracortical Injection

Published on: January 16, 2026

Area of Science:

  • Neuro-oncology
  • Medical oncology

Background:

  • Brain metastases occur in approximately 10% of cancer patients.
  • Increasing incidence of brain metastases is observed due to improved systemic cancer treatment and the blood-brain barrier.
  • Brain metastases can be the initial presentation of cancer.

Purpose of the Study:

  • To review definitive and supportive care for brain metastases.
  • To highlight the importance of judicious pharmacologic agent selection.
  • To discuss potential side effects of commonly used medications.

Main Methods:

  • Review of current diagnostic and therapeutic approaches for brain metastases.
  • Analysis of treatment strategies based on lesion number, location, and cancer stage.
  • Evaluation of pharmacologic and nonpharmacologic supportive care options.

Main Results:

  • Treatment selection is guided by metastasis characteristics and overall cancer stage.
  • Appropriate care can enhance both quality and duration of life for patients.
  • Injudicious medication use can worsen patient quality of life due to side effects.

Conclusions:

  • Management of brain metastases requires a dual approach: definitive care for the lesions and supportive care for symptoms.
  • Careful consideration of medication side effects is essential for optimizing patient well-being.
  • Optimized treatment strategies can significantly improve outcomes for patients with brain metastases.